[en] Introduction: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease, affecting a quarter of the world's adult population. NAFLD is closely related to type 2 diabetes mellitus (T2DM), obesity and metabolic syndrome. The evolution of the pathology is still uncertain, but it is known that the presence of fibrosis is the main predictor of disease progression, complications, and mortality, therefore identifying the presence of advanced fibrosis is of vital importance. Objective: to estimate the prevalence of advanced NASH in a population with DM2 and to define its phenotypic characteristics. Material and methods: the data of 577 patients with T2DM who successively attended consultations for their routine check-up were analyzed. The sample studied included 265 (45.8%) men and 312 (54.2%) women, with a mean age of 65.4 } 7.8 years, a mean BMI of 31.50 } 5.36 Kg/ m2 and a T2DM evolution time of 12.9 } 8.56 years. Subjects were clinically evaluated, 4 indirect fibrosis test were performed (APRI, NAFLD Fibrosis Score, FIB-4, Hepamet Fibrosis Score) and transient hepatic elastography through FibroscanÒ with M and XL probe. A statistical analysis of the available data was performed with SPSS R version 22. Results: a prevalence of NAFLD with advanced fibrosis (3 F3) of 10% was observed. A statistically significant association was observed between advanced fibrosis and insulin resistance (IR) values measured by HOMA2-IR as well as with the degree of BMI and AC. No statistically significant association was found with the time of evolution of T2DM or with the degree of control. Conclusions: a significant proportion of patients with T2DM may present fibrosis in advanced stages (3 F3). The degree of IR, the BMI and the PC could be predictors of risk.

[gl] Introdución: A EHGNA e a causa mais comun de enfermidade hepatica cronica, afectando a unha cuarta parte da poboacion adulta mundial. A EHGNA esta intimamente relacionado coa DM2, a obesidade e a sindrome metabolica. A evolucion da patoloxia ainda e incerta, pero sabese que a presenza de fibrose e o principal predictor de progresion da enfermidade, complicacions e mortalidade, polo que e de vital importancia identificar a presenza de fibrose avanzada. Obxectivo: estimar a prevalencia de EHGNA avanzada nunha poboacion con DM2 e definir as suas caracteristicas fenotipicas. Material e metodos: analizaronse os datos de 577 pacientes con DM2 que acudiron sucesivamente as consultas para a sua revision de rutina. A mostra estudada incluiu 265 (45,8%) homes e 312 (54,2%) mulleres, cunha idade media de 65,4 } 7,8 anos, un IMC medio de 31,50 } 5,36 kg/m2 e un tempo de evolucion da DM2 de 12,9 } 8,56 anos. Avaliaronse clinicamente os suxeitos, realizaronse 4 indices indirectos de fibrose (APRI, NAFLD Fibrosis Score, FIB-4, Hepamet Fibrosis Score) e elastografia hepatica de transicion mediante Fibroscanâ con sonda M e XL. Realizouse unha analise estatistica dos datos disponibles con SPSS R version 22. Resultados: observouse unha prevalencia de EGHNA con fibrose avanzada (3 F3) do 10%. Observouse unha asociacion estatisticamente significativa entre a fibrose avanzada e os valores de RI medidos por HOMA2-IR, asi como co grao de IMC e PC. Non se atopou ningunha asociacion estatisticamente significativa co tempo de evolucion da DM2 nin co grao de control da mesma. Conclusions: unha proporcion significativa de pacientes con DM2 poden presentar fibrose en fases avanzadas (3 F3). O grao de RI, o IMC e o PC poderian ser predictores de risco de fibrose.